Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase 3 KEYNOTE-062 study
Authors
Tabernero, Jvan Cutsem, E
Bang, Y
Fuchs, C
Wyrwicz, L
Lee, K
Kudaba, I
Garrido, M
Chung, C
Salguero, CC
Mansoor, Was
Braghiroli, M
Goekkurt, E
Chao, J
Wainberg, Z
Kher, U
Shah, S
Karg, S
Shitara, K
Affiliation
Vall d’Hebron University Hospital and Institute of Oncology (VHIO), BarcelonaIssue Date
2019
Metadata
Show full item recordCitation
Tabernero J, Van Cutsem E, Bang Y-J, Fuchs CS, Wyrwicz L, Lee KW, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. Ann Oncol, 30(Supplement_4).Journal
Annals of OncologyDOI
10.1093/annonc/mdz183.001Additional Links
https://dx.doi.org/10.1093/annonc/mdz183.001Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz183.001